NCT00803244View on ClinicalTrials.gov

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

381

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

January 31, 2010

Conditions
Primary Disease
Interventions
DRUG

300 IR

300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season

DRUG

Placebo

Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season

Trial Locations (6)

92183

Stallergenes Sa, Antony

Unknown

Hop Montauban, Montauban

Cab medical, Orange

Azienda Ospedaliera, Parma

Complejo Hospitalario de Caceres, Cáceres

HGU La Paz, Madrid

Sponsors

Lead Sponsor

Stallergenes Greer
All Listed Sponsors
lead

Stallergenes Greer

INDUSTRY